These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 37047329)

  • 1. Mesoporous Silica Nanoparticles as a Potential Nanoplatform: Therapeutic Applications and Considerations.
    Djayanti K; Maharjan P; Cho KH; Jeong S; Kim MS; Shin MC; Min KA
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesoporous silica nanoparticles for therapeutic/diagnostic applications.
    Jafari S; Derakhshankhah H; Alaei L; Fattahi A; Varnamkhasti BS; Saboury AA
    Biomed Pharmacother; 2019 Jan; 109():1100-1111. PubMed ID: 30551360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery: an update.
    Castillo RR; Lozano D; González B; Manzano M; Izquierdo-Barba I; Vallet-Regí M
    Expert Opin Drug Deliv; 2019 Apr; 16(4):415-439. PubMed ID: 30897978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo bio-safety evaluations and diagnostic/therapeutic applications of chemically designed mesoporous silica nanoparticles.
    Chen Y; Chen H; Shi J
    Adv Mater; 2013 Jun; 25(23):3144-76. PubMed ID: 23681931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multifunctional mesoporous silica nanoparticles for biomedical applications.
    Xu B; Li S; Shi R; Liu H
    Signal Transduct Target Ther; 2023 Nov; 8(1):435. PubMed ID: 37996406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Review on Recent Technologies and Patents on Silica Nanoparticles for Cancer Treatment and Diagnosis.
    Gupta A; Kushwaha SS; Mishra A
    Recent Pat Drug Deliv Formul; 2020; 14(2):126-144. PubMed ID: 32928094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosafety of mesoporous silica nanoparticles; towards clinical translation.
    Lérida-Viso A; Estepa-Fernández A; García-Fernández A; Martí-Centelles V; Martínez-Máñez R
    Adv Drug Deliv Rev; 2023 Oct; 201():115049. PubMed ID: 37573951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesoporous silica nanoparticles: synthesis, biocompatibility and drug delivery.
    Tang F; Li L; Chen D
    Adv Mater; 2012 Mar; 24(12):1504-34. PubMed ID: 22378538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systemic review on development of mesoporous nanoparticles as a vehicle for transdermal drug delivery.
    Kolimi P; Narala S; Youssef AAA; Nyavanandi D; Dudhipala N
    Nanotheranostics; 2023; 7(1):70-89. PubMed ID: 36593800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tailored Mesoporous Silica Nanoparticles for Controlled Drug Delivery: Platform Fabrication, Targeted Delivery, and Computational Design and Analysis.
    She X; Chen L; Yi Z; Li C; He C; Feng C; Wang T; Shigdar S; Duan W; Kong L
    Mini Rev Med Chem; 2018; 18(11):976-989. PubMed ID: 27145854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review on the latest developments of mesoporous silica nanoparticles as a promising platform for diagnosis and treatment of cancer.
    Ahmadi F; Sodagar-Taleghani A; Ebrahimnejad P; Pouya Hadipour Moghaddam S; Ebrahimnejad F; Asare-Addo K; Nokhodchi A
    Int J Pharm; 2022 Sep; 625():122099. PubMed ID: 35961417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesoporous Silica Nanoparticles: Drug Delivery Vehicles for Antidiabetic Molecules.
    Sarkar S; Ekbal Kabir M; Kalita J; Manna P
    Chembiochem; 2023 Apr; 24(7):e202200672. PubMed ID: 36719179
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesoporous Silica Nanoparticles-Based Nanoplatforms: Basic Construction, Current State, and Emerging Applications in Anticancer Therapeutics.
    Feng Y; Liao Z; Li M; Zhang H; Li T; Qin X; Li S; Wu C; You F; Liao X; Cai L; Yang H; Liu Y
    Adv Healthc Mater; 2023 Jun; 12(16):e2201884. PubMed ID: 36529877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mesoporous Silica Platforms with Potential Applications in Release and Adsorption of Active Agents.
    Chircov C; Spoială A; Păun C; Crăciun L; Ficai D; Ficai A; Andronescu E; Turculeƫ ȘC
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32825791
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advancements in mesoporous silica nanoparticles towards therapeutic applications for cancer.
    Li T; Shi S; Goel S; Shen X; Xie X; Chen Z; Zhang H; Li S; Qin X; Yang H; Wu C; Liu Y
    Acta Biomater; 2019 Apr; 89():1-13. PubMed ID: 30797106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomedical application of mesoporous silica nanoparticles as delivery systems: a biological safety perspective.
    Hosseinpour S; Walsh LJ; Xu C
    J Mater Chem B; 2020 Nov; 8(43):9863-9876. PubMed ID: 33047764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesoporous silica nanoparticles in drug delivery and biomedical applications.
    Wang Y; Zhao Q; Han N; Bai L; Li J; Liu J; Che E; Hu L; Zhang Q; Jiang T; Wang S
    Nanomedicine; 2015 Feb; 11(2):313-27. PubMed ID: 25461284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mesoporous Silica Nanoparticles as a Prospective and Promising Approach for Drug Delivery and Biomedical Applications.
    Pu X; Li J; Qiao P; Li M; Wang H; Zong L; Yuan Q; Duan S
    Curr Cancer Drug Targets; 2019; 19(4):285-295. PubMed ID: 30520373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in Functionalized Mesoporous Silica Nanoparticles for Tumor Targeted Drug Delivery and Theranostics.
    Zhang W; Liu M; Liu A; Zhai G
    Curr Pharm Des; 2017; 23(23):3367-3382. PubMed ID: 27784244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesoporous silica nanoparticles with organo-bridged silsesquioxane framework as innovative platforms for bioimaging and therapeutic agent delivery.
    Du X; Li X; Xiong L; Zhang X; Kleitz F; Qiao SZ
    Biomaterials; 2016 Jun; 91():90-127. PubMed ID: 27017579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.